Humira (adalimumab)

Published Online: Sunday, January 1, 2006

Abbott Laboratories (Chicago, Ill) recently received FDA approval of Humira for reducing the signs and symptoms of active arthritis in patients with psoriatic arthritis. The product is also indicated for reducing the signs and symptoms, including major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderate-to-severe active rheumatoid arthritis. The recommended dosage regimen for Humira for adult patients with rheumatoid arthritis or psoriatic arthritis is 40 mg administered every other week as a subcutaneous injection. The product is supplied in single- use, 1-mL prefilled glass syringes as a sterile, preservative-free solution for subcutaneous administration. For more information, visit

Latest Articles
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Latest Issues